Literature reviews, generated by AI
Ask a question. Get a review grounded in recent research.
PubMed research · Cited sources
Ask a question. Get a review grounded in recent research.
PubMed research · Cited sources
6 free credits, then one-time credit packs from $5.
No established treatment specifically targets or reverses Modic type 2 changes in patients with chronic sciatica or lumbar radiculopathy. These imaging findings may be associated with vertebral end-plate and adjacent marrow changes and can occur with degenerative disc disease, but they do not independently establish infection, nerve-root inflammation, or the source of sciatic symptoms. Management should therefore identify and treat the clinically concordant cause of radiculopathy, most often disc herniation or foraminal, lateral-recess, or central canal stenosis. Initial care is generally conservative and function-focused, with targeted injections considered for selected patients requiring short-term relief and decompression reserved for persistent disabling symptoms or neurological deterioration associated with confirmed nerve-root compression. Modic type 2 changes alone do not justify antibiotics, spinal fusion, or other invasive Modic-directed treatment.
Question: What's the best treatment for patients which type 2 Modic changes with chronic sciatica nerve inflammations
Read the full reviewResearch directly connecting guava (Psidium guajava) with medical technology is limited. The available evidence concerns medtech-adjacent applications, including glucose-management interventions, nutraceutical and botanical formulations, analytical quality-control methods, and biomedical assessment of therapeutic effects. A randomized clinical study found that a supercritical CO₂ guava fruit extract attenuated postprandial blood-glucose increases in healthy adults, while an experimental study of ethanolic guava leaf extract reported dose-dependent improvements in glucose and lipid profiles in diabetic rabbits, with higher doses also associated with protection against diabetes-related hepatic and renal injury (PMID: 31277259; PMID: 41689321). Additional work established an HPLC-DAD-ELSD method for quantifying nine guava triterpenoids and characterized polysaccharides with α-glucosidase-inhibitory and antioxidant activities (PMID: 32168948; PMID: 27083799). Guava bark and leaf extracts have also been evaluated in pain and osteoarthritis models using biomedical and histopathological technologies (PMID: 25386462; PMID: 28829233). Nevertheless, no identified study directly examined a medical device, diagnostic platform, sensor, or complete medtech system. Current evidence therefore supports guava primarily as a pharmacological, nutraceutical, analytical, or botanical component for future medtech-adjacent products.
Question: Medtech title guava
Read the full reviewLa extubación del paciente neurocrítico puede fracasar pese a una prueba de ventilación espontánea satisfactoria y a parámetros respiratorios convencionales adecuados. El resultado depende de la interacción entre la reserva respiratoria, el estado neurológico, la función bulbar, la protección de la vía aérea, la tos y el manejo de secreciones. La evidencia suministrada identifica como factores asociados con fracaso la tos débil o ausente, las secreciones moderadas o abundantes, la disfagia, la alteración de los reflejos protectores, un bajo componente motor del Glasgow, la ventilación mecánica prolongada y determinados indicadores de gravedad. Sin embargo, el Glasgow aislado, la modalidad de la prueba de ventilación espontánea y los índices respiratorios tradicionales tienen capacidad limitada cuando se emplean individualmente. La ecografía diafragmática, el flujo máximo de tos, la presión inspiratoria máxima y modelos como VISAGE pueden mejorar la estratificación, aunque requieren validación adicional. La decisión debe ser individualizada y multidimensional.
Question: Predictores de Extubación en neurocritico
Read the full reviewThree-dimensional prediction of T-cell receptor–peptide–major histocompatibility complex (TCR–pMHC) structures has progressed substantially, but accuracy remains dependent on the modeling strategy, complex type, structural feature, and evaluation metric. Flexible-backbone docking, specialized comparative-modeling pipelines, multimeric deep-learning architectures, and ensemble-generation methods have each addressed distinct limitations. TCRpMHCmodels, TCRmodel2, AlphaFold2, and AlphaFold3 have shown strong performance in different settings, while HADDOCK and specialized docking protocols can benefit from informative interface restraints or characteristic TCR–pMHC geometry. Nevertheless, CDR3 loops, peptide positioning, docking orientation, interface geometry, MHC class II complexes, and binding-affinity or specificity inference remain difficult. Global structural similarity may therefore obscure biologically important local errors. Current predictors are most appropriately used as complementary, hypothesis-generating tools, with model assessment based on multiple global, interface-focused, and functional criteria and with experimental validation retained as an essential step.
Question: performance of 3d structure prediction methods on TCR-pMHC complexes
Read the full reviewThe supplied evidence indicates that pioglitazone and related PPARγ agonists promote adipogenic remodeling, but it does not resolve whether they recruit primitive adipose stem cells, commit previously uncommitted progenitors, or primarily differentiate pre-existing committed preadipocytes. The strongest direct evidence is a short-term deuterium-labeling study showing increased generation of cells in both mature adipocyte and stromal-vascular compartments during pioglitazone exposure, consistent with precursor involvement and new adipocyte production (PMID: 22124466). However, the heterogeneous stromal-vascular fraction, absence of lineage tracing, and limited treatment duration prevent identification of the responsible progenitor population or assessment of long-term self-renewal. Related studies support PPARγ-dependent adipogenic differentiation, matrix remodeling, and possible clonal expansion in experimental systems, but remain indirect for pioglitazone action in normal human adipose tissue (PMID: 16799780; PMID: 16873539; PMID: 21572083; PMID: 12529376; PMID: 28957413). Overall, differentiation of adipogenically competent precursor cells is the best-supported interpretation, whereas recruitment of primitive stem cells and preservation of durable progenitor self-renewal remain unproven.
Question: does pioglitazone recruit proliferating adipose stem cells, commit uncommitted progenitors, or merely terminally differentiate an existing committed preadipocyte pool? what evidence from lineage tracing, deuterium labeling, clonal analysis, or serial human biopsies indicates whether chronic treatment preserves progenitor self-renewal and long-term hyperplastic capacity?
Read the full reviewPioglitazone improves insulin sensitivity and promotes subcutaneous adipose storage, but its ability to preferentially increase femoral rather than abdominal adipogenesis remains incompletely established. Human evidence indicates that pioglitazone can stimulate formation of new adipocytes in femoral subcutaneous fat while reducing relative visceral adiposity in women with obesity, although other studies demonstrate increased total subcutaneous fat without proving femoral selectivity (PMID: 33001232; PMID: 11887166; PMID: 12050251; PMID: 19910937; PMID: 21272186). Potential complementary pathways include adiponectin–AMPK signaling, 11β-HSD1/cortisol reduction, dietary fatty-acid optimization, BMP-mediated progenitor recruitment, angiogenesis, extracellular-matrix remodeling, insulin signaling, FGF21, and α2-adrenergic mechanisms. Adiponectin–AMPK offers the best balance of metabolic plausibility, reversibility, and safety, whereas depot-targeted BMP signaling has the greatest theoretical selectivity but limited translational support. Reducing abdominal glucocorticoid drive may improve the femoral-to-abdominal ratio indirectly by restraining abdominal expansion. No cited human study has directly tested these combinations or established a femoral-to-abdominal adipogenesis ratio. Accordingly, these strategies remain hypothesis-generating and should prioritize regional adipose measurements, edema surveillance, fibrosis assessment, and progenitor biology.
Question: which modifiable pathways could synergize with pioglitazone to increase the femoral-to-abdominal adipogenesis ratio—α2-adrenergic signaling, 11β-HSD1/cortisol, insulin, adiponectin–AMPK, FGF21, BMP signaling, angiogenesis, extracellular-matrix remodeling, or specific dietary fatty acids? rank candidates by depot selectivity, human evidence, expected effect size, reversibility, and risks such as generalized fat gain, edema, fibrosis, or progenitor depletion.
Read the full reviewDuring caloric surplus, pioglitazone could plausibly increase the storage capacity of subcutaneous adipose tissue through PPARγ activation, improved insulin sensitivity, adipocyte differentiation, and adipose remodeling. A mixed meal could theoretically combine chylomicron-triacylglycerol delivery with insulin-stimulated glucose uptake, glycerol-3-phosphate availability, suppression of lipolysis, and triacylglycerol re-esterification. However, the supplied evidence does not demonstrate that pioglitazone, meal composition or timing, postprandial insulin, gluteal resistance exercise, local heat, or altered adipose blood flow selectively increases femoral uptake or long-term trapping of meal-derived fatty acids. The proposed mechanism would require coordinated, depot-specific activity of lipoprotein lipase (LPL), CD36, acyl-CoA synthetase long-chain enzymes (ACSL), and diacylglycerol acyltransferase (DGAT), together with sufficient perfusion and intracellular retention. Skeletal muscle may compete for circulating fatty acids after exercise, and increased uptake must be distinguished from net retention and chronic adipocyte expansion. Overall, selective femoral partitioning remains a mechanistic hypothesis rather than an established intervention effect (PMID: 21721180; PMID: 23949610; PMID: 25969149; PMID: 27539147).
Question: during caloric surplus, can meal composition or timing, postprandial insulin, glute resistance exercise, local heat, or altered adipose perfusion selectively increase femoral uptake and trapping of meal-derived fatty acids during pioglitazone treatment? evaluate LPL, CD36, ACSL, DGAT, adipose blood flow, re-esterification, and skeletal-muscle competition, and distinguish acute substrate uptake from lasting adipocyte hyperplasia.
Read the full reviewDifferential responsiveness to pioglitazone among human adipose progenitors is best interpreted as variation in PPARγ pathway competence within distinct depot-specific developmental and cellular contexts. The available evidence does not support total PPARG abundance, or alternative PPARG isoform usage alone, as a sufficient explanation. Instead, PPARG2 induction and activity, RXR heterodimer competence, adipogenic commitment, BMP–WNT signaling, developmental identity, extracellular-matrix properties, and inflammatory or vascular context may interact to establish different thresholds for terminal adipogenesis. The strongest direct evidence concerns depot-dependent adipogenic competence and WNT-related regulation, including LRP5-associated effects in paired gluteal and abdominal progenitors (PMID: 25651180). Evidence from subcutaneous–omental comparisons further indicates that PPARG expression, PPARG2 inducibility, and RXRα availability may contribute, although these findings remain an extrapolation for femoral/gluteal–abdominal comparisons (PMID: 11872672; PMID: 9399962). Overall, pioglitazone appears to act on pre-existing depot states rather than uniformly overcoming upstream constraints.
Question: in paired human femoral/gluteal and abdominal adipose progenitors, which molecular features explain differential responsiveness to pioglitazone—PPARG abundance or isoforms, RXR/coactivator availability, CEBPA, ZNF423, BMP–WNT signaling, HOX/TBX15 developmental identity, extracellular-matrix stiffness, vascularity, or inflammatory state—and which of these features are plausibly modifiable in vivo?
Read the full reviewBartter syndrome comprises a group of usually autosomal-recessive renal salt-wasting tubulopathies caused by impaired sodium, potassium, and chloride reabsorption, primarily in the thick ascending limb of Henle’s loop and, in some phenotypes, the distal nephron. Salt and volume depletion activate the renin–angiotensin–aldosterone system, producing hypokalemic, hypochloremic metabolic alkalosis, elevated renin activity, secondary hyperaldosteronism, polyuria, and usually normal or low blood pressure. Disease severity ranges from severe antenatal or neonatal disease with polyhydramnios, prematurity, dehydration, and growth impairment to milder classic presentations later in childhood or adulthood. Genetic heterogeneity contributes to variable urinary calcium excretion, nephrocalcinosis, hypomagnesemia, and extra-renal manifestations. Molecular testing supports diagnosis and subtype classification, while treatment requires individualized lifelong replacement of fluids and electrolytes, monitoring for renal complications, and, in selected patients, reduction of prostaglandin-mediated losses.
Question: Bartter
Read the full reviewBartter syndrome is a rare, genetically heterogeneous inherited renal salt-wasting disorder caused primarily by impaired sodium and chloride reabsorption in the thick ascending limb of the loop of Henle, with some subtypes involving the distal convoluted tubule. Transport defects produce extracellular-fluid depletion, activation of the renin–angiotensin–aldosterone system, and renal potassium and hydrogen-ion loss, resulting in hypokalemic, hypochloremic metabolic alkalosis despite normal or low blood pressure. Clinical severity ranges from life-threatening antenatal disease with polyhydramnios, prematurity, severe neonatal polyuria, and dehydration to milder childhood or adult presentations. Hypercalciuria and nephrocalcinosis are especially characteristic of antenatal and classic forms. Diagnosis relies on clinical and biochemical assessment, supplemented by genetic testing, while treatment requires individualized fluid and electrolyte replacement and, in selected patients, nonsteroidal anti-inflammatory therapy. Early recognition is particularly important in neonatal disease, in which salt and water losses can progress rapidly.
Question: Bartter diasease
Read the full review